If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

BPH Surgical Approaches Compared

May 19, 2012

Transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH) is associated with an increased risk of complications but a significantly lower risk of repeat BPH surgery compared to minimally-invasive surgeries, according to a poster presentation at the American Urological Association 2012 annual meeting.
 

BPH Surgery Complication Rates Underestimated

April 30, 2012

PARIS—Complication rates after surgery for benign prostatic hyperplasia (BPH) are higher in real clinical practice than in clinical trials.
 

Open Prostatectomy, TURP Are the Most Common BPH Surgeries

April 25, 2012

Despite the emergence of new surgical techniques to treat benign prostatic hyperplasia (BPH), open prostatectomy (OP) and monopolar transurethral resection of the prostate (TURP) remain the procedures used most by urologists, according to a recent survey.
 

Prostatic Artery Embolization Eases BPH Symptoms

March 27, 2012

SAN FRANCISCO—Benign prostatic hyperplasia (BPH) may be safely treated with prostatic artery embolization (PAE), according to a new study presented at the 37th Annual Scientific Meeting of the Society of Interventional Radiology (SIR).
 

NSAIDs Do Not Protect Against BPH/LUTS

March 21, 2012

Recent use of nonsteroidal anti-inflammatory agents (NSAIDs) do not protect against development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), a new study concluded.
 

Finasteride Prevents BPH, Study Finds

March 14, 2012

Finasteride use decreases the risk of clinical benign prostatic hyperplasia (BPH), according to researchers.
 

Severe Post-Transplant LUTS May Be Predictable

March 02, 2012

QUEBEC CITY—Evaluation of lower urinary tract symptoms (LUTS) using validated questionnaires prior to renal transplantation (Tx) may predict which patients will experience significant LUTS after transplantation, researchers reported at the Canadian Society of Transplantation annual meeting.
 

PDE-5 Inhibitors Improve LUTS in Men

February 26, 2012

PARIS—Phosphodiesterase-5 (PDE-5) inhibitors significantly improve lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and can be considered as an alternative treatment for BPH-related LUTS in men with or without erectile dysfunction, researchers reported at the 27th Annual Congress of the European Association of Urology.
 

Metabolic Syndrome Raises BPH Risk

February 25, 2012

PARIS—Metabolic syndrome increases a man's risk of developing benign prostatic hyperplasia (BPH) and the risk of prostatic inflammation in men who have BPH, according to reports at the 27th Annual Congress of the European Association of Urology.
 

Prostatic Urethral Lift Relieves Lower Urinary Tract Symptoms

January 03, 2012

Use of a prostatic urethral lift procedure, a minimally invasive treatment for lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH), preserves sexual function, according to a study published online ahead of print in The Journal of Sexual Medicine.
 

Study: Electromagnetic Treatment Improves BPH

December 19, 2011

Radiofrequency pulsed electromagnetic fields (EMF) may provide a non-invasive treatment for benign prostatic hyperplasia (BPH), researchers reported.
 

Epinephrine Can Cut TURP-Related Blood Loss

December 13, 2011

Epinephrine injected into the prostate can be used to decrease blood loss during transurethral resection of the prostate (TURP), according to researchers.
 

HoLEP's Benefits As BPH Treatment Durable Out to 10 Years

October 31, 2011

Holmium laser enucleation of the prostate (HoLEP) is an effective treatment for benign prostatic hyperplasia (BPH) that has long-term durable clinical outcomes, researchers concluded.
 

Saw Palmetto No More Effective than Placebo for BPH

October 14, 2011

Saw palmetto fruit extracts are widely used to treat lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH), but a new study shows that these extracts are no better than placebo at easing symptoms, according to investigators.
 

Erectile Dysfunction Drug Approved as BPH Treatment

October 08, 2011

The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men with both erectile dysfunction (ED) and BPH.
 

PCa More Likely in BPH Sufferers

October 01, 2011

Prostate cancer (PCa) is more likely to be diagnosed in men who have been hospitalized for clinical benign prostatic hyperplasia (BPH) or undergone surgery for the condition, according to a Danish study.
 

Higher CRP Levels Predict Residual Urgency in BPH Patients

August 31, 2011

GLASGOW—Serum C-reactive protein (CRP) levels, a marker of systemic inflammation, are associated with residual urgency after medical treatment for benign prostatic hyperplasia (BPH), according to new findings presented at the International Continence Society annual meeting.
 

Botulinum Toxin Injections Effective for BPH

August 30, 2011

GLASGOW—Intraprostatic injections of botulinum neurotoxin type A (BoNT-A) are a safe and effective treatment for benign prostatic hyperplasia (BPH), according to a study presented at the International Continence Society annual meeting.
 

Heavier Men Face Higher LUTS Risk

May 18, 2011

WASHINGTON, D.C.—Elderly men who are overweight or obese are at increased risk for developing lower urinary tract symptoms (LUTS), but those who engage in a relatively high level of physical activity or daily walking for exercise have a reduced risk, data show.
 

Severe Adverse BPH Outcomes Persist

May 18, 2011

WASHINGTON, D.C.—Severe adverse outcomes of benign prostatic hyperplasia (BPH) persist despite widespread use of oral therapies, according to a study presented at the American Urological Association 2011 annual meeting.
 

Overweight Young Men Face High Risk of Enlarged Prostates

May 17, 2011

WASHINGTON, D.C.—Overweight young men are more likely than normal-weight men to develop an enlarged prostate later in life, researchers reported.
 

Modest Weight Loss Does Not Prevent LUTS

May 17, 2011

WASHINGTON, D.C.—Although obesity has been linked with lower urinary tract symptoms (LUTS) in aging men, modest weight loss may not prevent onset or progression of LUTS in this population, new findings presented at the American Urological Association 2011 annual meeting suggest.
 

Statins May Improve Urologic Symptoms in Men

May 17, 2011

WASHINGTON, D.C.—Statin use may decrease the occurrence of lower urinary tract symptoms (LUTS) among men, but not women, researchers reported at the American Urological Association 2011 annual meeting.
 

African-American Men Less Likely to Receive BPH Treatment

May 17, 2011

WASHINGTON, D.C.—African American men are less likely to receive treatment for benign prostatic hyperplasia (BPH) compared with other races, according to findings presented at the American Urological Association 2011 annual meeting.
 

Outpatient BPH Procedure Works

March 29, 2011

CHICAGO—Prostatic artery embolization (PAE), a new outpatient interventional radiology treatment that blocks the blood supply to enlarged prostate glands, achieves outcomes similar to those of transurethral resection of the prostate (TURP), according to Portuguese researchers.
 

Botulinum Toxin Eases LUTS in Men

March 22, 2011

VIENNA—Botulinum toxin type A (BTA) injected into the prostate may be a safe and effective treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), according to preliminary study results presented here at the 26th Annual Congress of the European Association of Urology.
 

Novel Cause of BPH, PCa Proposed

March 22, 2011

VIENNA—Benign prostatic hyperplasia (BPH) and prostate cancer could be the result a previously unrecognized route of free testosterone flow from the testes to the prostate, according to investigators.
 

Tadalafil Helps Men with Both ED and BPH-LUTS

March 20, 2011

VIENNA—Tadalafil can improve erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men who suffer from both problems, data suggest.
 

AUA Updates BPH Guidelines

February 08, 2011

Updated American Urological Association (AUA) guidelines for treating benign prostatic hyperplasia (BPH) include recommendations that laboratory testing include a PSA test and a urinalysis to rule out infection or other causes of lower urinary tract symptoms (LUTS).
 

DHT Does Not Affect Prostate Growth

January 24, 2011

Dihydrotestosterone (DHT) treatment over two years does not halt prostate growth, according to study findings published in the Annals of Internal Medicine (2010;153:621-632).
 

Dutasteride May Decrease PCa Diagnosis Risk

January 05, 2011

Dutasteride (Avodart) treatment significantly reduces the relative risk of a prostate cancer (PCa) diagnosis in men with benign prostatic hyperplasia (BPH) undergoing screening with PSA tests and digital rectal examinations (DREs), new findings suggest.
 

Finasteride Has Long-Term Benefits in BPH Sufferers

January 05, 2011

Finasteride improves long-term urinary tract symptoms associated with benign prostatic hyperplasia (BPH) when compared with placebo, but it is less effective than the alpha blocker doxazosin
 

Silodosin Effective for LUTS Due to BPH

December 02, 2010

A new study provides more evidence that silodosin is an effective treatment for the relief of lower urinary tract symptoms (LUTS) in men with suspected benign prostatic hyperplasia (BPH).
 

Liquid Cooled Fiber for BPH Laser Treatment Launched

November 16, 2010

American Medical Systems (AMS) has launched the MoXy Liquid Cooled Fiber for laser treatment of benign prostatic hyperplasia (BPH).
 

High-Fat Diet May Harm the Prostate

September 24, 2010

A new study provides more evidence that a high-fat diet is a potential cause of prostatic diseases, including benign prostatic hyperplasia and prostate cancer.
 

Findings May Improve Use of BotulinumToxin for LUTS

September 24, 2010

SAN FRANCISCO—Baseline PSA and prostate volume may predict which patients may respond best to botulinum toxin type A (BoNT-A) treatment of lower urinary tract symptoms (LUTS), according to a study presented at the American Urological Association (AUA) annual meeting.
 

Cranberries May Relieve LUTS in Men

September 23, 2010

Dried cranberries may ease lower urinary tract symptoms (LUTS) in men, new findings suggest.
 

BPH Drugs May Enhance Prostate Cancer Detection

June 03, 2010

SAN FRANCISCO—Prostate biopsies performed after treatment with 5-alpha reductase inhibitors increase the rate of prostate cancer detection, researchers reported at the American Urological Association annual meeting.
 

Finasteride May Be a Better Choice for Lower Urinary Tract Symptoms

June 01, 2010

SAN FRANCISCO—Finasteride and dutasteride are similarly effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia in properly selected patients, but dutasteride is associated with significantly greater sexual side effects and breast complications, researchers reported.
 

Intraurethral Catheters Recommended

May 01, 2010

They cause fewer UTIs than indwelling catheters in men at high risk during anesthesia and surgery.
 

First Generic Tamsulosin Okayed for Treating BPH

April 27, 2010

The FDA has approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH).
 

Combined Regimen Is More Effective for BPH, Data Show

April 26, 2010

Dual therapy with tamsulosin and dutasteride is more effective than either agent alone in reducing the risk of progression in patients with benign prostatic hyperplasia (BPH).
 

HoLEP Safely Provides Durable BPH Outcomes

March 30, 2010

Even more than five years postoperatively, the procedure is associated with few complications.
 

BPH Again Linked to Inflammation

February 22, 2010

The condition is more likely to develop in men with high interleukin-6 or C-reactive protein levels.
 

CKD in Men With BPH-Related LUTS

December 15, 2009

Decreased peak flow rate and a history of hypertension and/or diabetes are significantly associated with CKD in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), according to investigators in Seoul, Korea.
 

BPH Drug May Raise Testosterone

November 19, 2009

Dutasteride treatment for benign prostatic hyperplasia (BPH) is associated with a significant increase in serum testosterone and a significant decrease in BMI among men with relatively lower baseline serum testosterone levels, researchers reported in BJU International (2009; published online ahead of print).
 

Severe Lower Urinary Tract System Linked to Obesity

November 18, 2009

A study of 602 Korean men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia found that those with a waist circumference greater than 90 cm (central obesity) had a 36% increased risk of severe LUTS compared with men who had smaller waists.
 

Light-Activated Drug for BPH Enters Phase 2 Clinical Trial

September 17, 2009

Researchers recently treated the first patients who are participating in a phase 2 clinical trial of a novel therapy for benign prostatic hyperplasia (BPH).
 

Finasteride Use by Men With BPH Cuts PCa Risk

September 17, 2009

Finasteride treatment reduces the risk of low-grade prostate cancer (PCa) in men taking the drug for symptomatic benign prostatic hyperplasia (BPH), data show.
 

Alfuzosin Hastens Catheter Removal

September 01, 2009

Use of alfuzosin 10 mg once daily increases the likelihood of a successful trial without catheter (TWOC) after acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH), according to researchers.
 

BPH Medication to Be Tested in an Extended Phase 3 Study

July 23, 2009

Æterna Zentaris Inc., of Quebec City, Canada, has announced the opening of an extended phase 3 study of cetrorelix, a treatment for benign prostatic hyperplasia (BPH).
 

Rapid Changes in Urinary Symptoms Linked to CRP

July 23, 2009

Rapid increases in irritative lower urinary tract symptoms (LUTS) and rapid decreases in peak urinary flow rates may be related to inflammatory processes, new research suggests.
 

HoLEP Safe With Anticoagulation

July 23, 2009

Holmium laser enucleation of the prostate (HoLEP) is a safe alternative to transurethral resection of the prostate (TURP) for patients on oral anticoagulation (OA) therapy, researchers reported in the Journal of Endourology (2009; published online ahead of print).
 

ED Following BPH Surgery

June 18, 2009

Iranian researchers who studied men undergoing prostate surgery for benign prostatic hyperplasia (BPH) found that 12.5% of those without erectile dysfunction (ED) before surgery developed the condition postoperatively.
 

PVP for Enlarged Prostate Provides Durable Results

April 09, 2009

Photoselective vaporization of the prostate (PVP) provides long-term improvements in men suffering from benign prostate hyperplasia with obstruction.
 

Combo May Ease Refractory Nocturia

April 02, 2009

Adding a diuretic to alpha-blocker therapy may be an effective second-line treatment for nocturia in some men with lower urinary tract symptoms (LUTS), according to researchers.
 

Intermittent Therapy May Be an Option for LUTS

March 20, 2009

Intermittent alpha blocker therapy is a feasible strategy for men suffering from lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO), a researcher has concluded.
 

Prostate Cancer Found in 10% of Men Having BPH Surgery

March 20, 2009

German researchers found that one in 10 men undergoing laser surgery for benign prostatic hyperplasia (BPH) also had prostate cancer (PCa).
 

Risk Factors for Post-TURP Urinary Tract Infections Identified

March 20, 2009

Patients who have urinary catheters in place upon hospital admission for transurethral resection of the prostate (TURP) are at increased risk of post-operative urinary tract infections (UTIs), investigators reported at the 24th Annual European Association of Urology Congress in Stockholm.
 

Alfuzosin Treatment for BPH Improves Sexual Function

March 17, 2009

Patients who receive alfuzosin as treatment for benign prostatic hyperplasia (BPH) experience improvements in sexual function as well lower urinary tract symptoms (LUTS), a South Korean study suggests.
 

GreenLight Laser Effective for LUTS

March 17, 2009

SHANGHAI—Laser vaporization of prostate tissue using a 120-watt GreenLight laser significantly reduces lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), according to a study conducted at nine centers in seven countries.
 

Persistent Nocturia? Diuretic May Help

March 06, 2009

Adding a diuretic to alpha-blocker therapy may be an effective second-line treatment for nocturia in some men with lower urinary tract symptoms (LUTS), according to researchers.
 

Two Drugs Better than One for LUTS

January 22, 2009

Combination therapy with tamsulosin and extended-release oxybutynin is superior to tamsulosin alone in treating men with lower urinary tract symptoms (LUTS), data show.
 

TURP Is Inferior for Prostate Cancer Detection

December 29, 2008

Transurethral resection of the prostate (TURP) is effective for treating benign prostatic obstruction, but it is not reliable for detecting cancer, data show.
 

GreenLight HPS Laser Found Safe and Effective for BPH

December 22, 2008

A short-term follow-up study shows that GreenLight HPS laser photoselective vaporization prostatectomy (PVP) is safe and effective for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH), according to a report in the Journal of Endourology (2008;22:2341-2347).
 

Ethanol May Be a BPH Option

December 10, 2008

Transurethral ethanol injection may be a treatment options for some men with benign prostatic hyperplasia (BPH), long-term study data suggest.
 

BPH Drugs Not a Hip Fracture Risk

November 01, 2008

Use of 5-α reductase inhibitors for benign prostatic hyperplasia (BPH) does not significantly increase the risk of hip fracture, researchers conclude.
 

BPH Appears Less Prevalent in Blacks

November 01, 2008

Benign prostatic hyperplasia (BPH) is reported significantly less often among blacks than whites, according to a study of 21,949 men. Despite an apparently lower prevalence of BPH, blacks with BPH are more likely than whites to have had surgery for the condition.
 

Finasteride Shrinks Prostates of Any Size, Study Suggests

September 01, 2008

Long-term treatment with finasteride either alone or in combination with doxazosin is associated with clinically significant reductions in total prostate volume in patients with lower urinary tract symptoms (LUTS) and BPH, regardless of baseline prostate size, data show.
 

LUTS Identified As Risk Factor for Falls

August 28, 2008

ORLANDO—Elderly men with moderate or severe lower urinary tract symptoms (LUTS) are at significantly greater risk for falls, and the risk dramatically increases as the symptoms worsen, data show.
 

New Indication for Combo to Treat Enlarged Prostate

August 28, 2008

GlaxoSmithKline has received a new indication for Avodart (dutasteride) in combination with the alpha blocker tamsulosin for the treatment of symptomatic enlarged prostate, a disease affecting half of all men over age 50.
 

Celecoxib Works for BPH with Nocturia

August 19, 2008

Celecoxib is effective for treating BPH patients with refractory nocturia, researchers in Iran reported in Urology (2008; online ahead of print).
 

HoLEP Effectiveness Independent Prostate Size

July 22, 2008

Holmium laser enucleation of the prostate (HoLEP) is safe and effective for treating symptomatic BPH independent of prostate size, according to a report in BJU International (2008;101:1536-1541).
 

Combo Improves BPH-Related Quality of Life

July 11, 2008

MILAN—Dutasteride and tamsulosin combination therapy provides significantly greater improvements in patient-reported, symptom-specific quality of life compared with either medication at two years in men with moderate to severe BPH, new data show.
 

Agency to Consider Silodosin to Treat BPH

May 06, 2008

The FDA has accepted a New Drug Application for silodosin, a novel alpha1-adrenoreceptor antagonist, from Watson Pharmaceuticals, Inc., of Corona, Calif. Watson is seeking approval of silodosin for the treatment of BPH symptoms.
 

Study: LUTS in Men Linked To Diabetes

May 06, 2008

Irritative lower urinary tract symptoms (LUTS) and nocturia are positively associated with diabetes, a study found. The relationship is greater in black than white men.
 

BP Surges Occur During TUMT

May 05, 2008

BP surges occur in many men undergoing transurethral microwave therapy (TUMT) for BPH, according to researchers at the Mayo Clinic in Rochester, Minn.
 

Study: Prostatitis May Increase BPH Risk

May 01, 2008

Physician-diagnosed prostatitis is associated with 2.4-fold increased risk of a later diagnosis of BPH and a 70% increased risk of requiring later treatment for that condition, according to a study published in Urology (2008;71:475-479).
 

HoLEP Efficacy for BPH Increases with Prostate Size

April 10, 2008

The efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of symptomatic BPH increases with prostate size, according to researchers in India.
 

Lower BPH Risk Linked to Greater Vegetable Intake

April 10, 2008

A diet high in vegetable intake is associated with a lower risk of surgically treated BPH, according to Australian researchers.
 

Exercise May Lower BPH, LUTS Risk

April 07, 2008

Physical activity reduces the risk of BPH and lower urinary tract symptoms (LUTS), according to a review of studies that included a total of 43,083 men.
 

Antibody Assay Could Aid in Assessing Prostate Disease

January 01, 2008

Using an assay they developed to detect antibodies to Propionibacterium acnes bacteria, researchers have found a link between these bacteria and development of inflammation-related prostate diseases.
 

Novel Agent Eases BPH-Related LUTS

December 01, 2007

PARIS—Ozarelix, an investigational agent, may be effective for selected men with lower urinary tract symptoms (LUTS) associated with BPH, phase II trial data suggest. The drug is a highly soluble luteinizing hormone releasing antagonist.
 

Study: BPH Medications' Efficacy Not Equal

November 01, 2007

PARIS—Dutasteride is more effective than tamsulosin for treating men with moderate-to-severe urinary symptoms of BPH, data suggest.
 

Combo May Be More Effective for LUTS

November 01, 2007

PARIS—Men with lower urinary tract symptoms (LUTS) associated with BPH may benefit more from a combination of tolterodine extended-release and tamsulosin than from either medication alone.
 

Sildenafil Benefits LUTS Patients, Easing Muscles

September 01, 2007

ANAHEIM, Calif.--Sildenafil taken daily improves lower urinary tract symptoms (LUTS) secondary to BPH similar to alpha blockers and 5-α-reductase inhibitors, a new trial indicates.
 

New GnRH Antagonist Shows Promise for LUTS

August 30, 2007

ANAHEIM, Calif.—Ozarelix, a GnRH antagonist given intramuscularly, is well tolerated and has significant and clinically meaningful efficacy in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH, a study shows.
 

PCPs May Miss LUTS Cases

August 01, 2007

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.
 

Laser Meets the BPH Gold Standard

August 01, 2007

For 30 years, lasers have been evolving for the treatment of urologic conditions. Investigators focused on lasers for BPH to achieve results similar to transurethral resection of the prostate (TURP) without the bleeding, fluid overload, blood loss, inpatient hospital stays of two to three days, and erectile dysfunction associated with TURP.
 

Bladder Cancer Risk Higher in TURP-Treated BPH Patients

July 01, 2007

A study of Swedish men with BPH found no excess risk of bladder cancer, but did show that the likelihood of the malignancy is elevated in those who undergo transurethral resection of the prostate (TURP), especially men with comorbid genitourinary tract conditions.
 

Botox Better Than Expected

July 01, 2007

ANAHEIM, Calif.—Just one injection of botulinum toxin type A (Botox) into the prostate may provide relief from BPH-related lower urinary tract symptoms (LUTS) for up to 12 months.
 

Higher Prostate Cancer Risk Found in BPH Drug Users

May 08, 2007

Men who take finasteride or alpha blockers for BPH are at higher risk of prostate cancer than non-users, investigators in Finland conclude.
 

PVP, TURP Outcomes Similar

May 08, 2007

Photoselective vaporization of the prostate (PVP) for BPH provides outcomes similar to those of transurethral resection of the prostate (TURP).
 

Botulinum Toxin Could Be Useful As a BPH Treatment

May 08, 2007

Botulinum toxin type A (BTX-A) injections may be a promising treatment for BPH patients with urinary retention who are not candidates for surgery.
 

IPP May Aid BPH Management

May 04, 2007

Intravesical prostatic protrusion (IPP) is a useful predictor of outcomes in patients with BPH, studies show.
 

New Surgical Options for BPH Must Measure Up

March 01, 2007

The past two decades have witnessed the introduction a dizzying array of minimally-invasive surgical alternatives to the gold standard treatments for BPH—transurethral resection of the prostate (TURP) and the open simple prostatectomy.
 

New Blood Test Can Diagnose Severe BPH

March 01, 2007

Researchers have developed a new blood test that can distinguish severely symptomatic BPH from BPH that occurs with few if any symptoms, even if men have prostate cancer. The assay measures serum levels of a protein called JM-27.
 

Drug for Baldness Affects PSA Testing

March 01, 2007

As little as 1 mg/day of finasteride can seriously distort the results of a PSA screening for prostate cancer, a recent study has found.
 

Metabolic Syndrome and BPH

February 01, 2007

Prostate growth in men with benign prostatic hyperplasia (BPH) is increased in the presence of the metabolic syndrome, according to a study that supports a causative role for hyperinsulinemia.
 

Application and Study Protocol Accepted for BPH Drug

February 01, 2007

Spectrum Pharmaceuticals, Inc., of Irvine, Calif., has announced the FDA’s acceptance of its Investigational New Drug application for ozarelix for the treatment of benign prostatic hyperplasia (BPH) and approval of a phase IIb study of the drug.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Overactive Bladder Prostate Cancer Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urinary Tract Infection Urology UTI

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions